DAURISMO
Drug
PFIZER INC.
Total Payments
$15.8M
Transactions
1,422
Doctors
183
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $671,893 | 9 | 1 |
| 2023 | $893,622 | 34 | 10 |
| 2022 | $1.2M | 65 | 11 |
| 2021 | $2.3M | 149 | 14 |
| 2020 | $4.9M | 369 | 57 |
| 2019 | $4.7M | 552 | 127 |
| 2018 | $1.2M | 244 | 32 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15.3M | 978 | 97.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $238,010 | 170 | 1.5% |
| Consulting Fee | $146,738 | 63 | 0.9% |
| Honoraria | $78,984 | 24 | 0.5% |
| Travel and Lodging | $5,249 | 18 | 0.0% |
| Food and Beverage | $2,191 | 40 | 0.0% |
| Education | $1,373 | 129 | 0.0% |
Payments by Type
Research
$15.3M
978 transactions
General
$472,545
444 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED 11 DOUBLEBLIND MULTICENTER PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB PF04449913 OR AZACITIDINE AZA WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA | PFIZER INC. | $6.8M | 5 |
| PHASE II STUDY OF THE COMBINATION OF GLASDEGIB AND CPX351 IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA WITH MDS RELATED CHANGES OR THERAPYRELATED ACUTE MYELOID LEUKEMIA A UNIVERSITY OF CALIFORNIA HEMATOLOGIC MALIGNANCIES CONSORTIUM | PFIZER INC. | $4.3M | 0 |
| AN OPENLABEL PHASE 1B STUDY OF PF04449913 GLASDEGIB IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED HIGHERRISK MYELODYSPLASTIC SYNDROME ACUTE MYELOID LEUKEMIA OR CHRONIC MYELOMONOCYTIC LEUKEMIA | PFIZER INC. | $1.9M | 0 |
| WI242315 A SINGLEARM OPENLABEL PHASE III STUDY OF GLASDEGIB FOR SCLEROTIC CHRONIC GRAFTVSHOST DISEASE | PFIZER INC. | $581,552 | 0 |
| A HEPATIC IMPAIRMENT CLINICAL PHARMACOLOGY STUDY OF PF04449913 | PFIZER INC. | $492,998 | 0 |
| A RENAL IMPAIRMENT CLINICAL PHARMACOLOGY STUDY OF PF04449913 | PFIZER INC. | $446,235 | 0 |
| A PHASE 1B2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF04449913 AN ORAL HEDGEHOG INHIBITOR IN COMBINATION WITH INTENSIVE CHEMOTHERAPY LOW DOSE ARAC OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGHRISK MYELODYSPLASTIC SYNDROME | PFIZER INC. | $269,986 | 0 |
| WI244737 A GLASDEGIBBASED PRECISION MEDICINE PHASE I TRIAL FOR POSTTRANSPLANT RELAPSED AML | PFIZER INC. | $220,176 | 0 |
| WI244219 A RANDOMIZED PHASE 2 CLINICAL TRIAL OF THE COMBINATION OF GLASDEGIB PF04449913 WITH TWO STANDARD DECITABINE REGIMENS FOR POORRISK ACUTE MYELOID LEUKEMIA | PFIZER INC. | $143,827 | 0 |
| AML CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $84,870 | 17 |
| A PHASE 2 STUDY OF PF04449913 FOR THE TREATMENT OF ACUTE LEUKEMIA PATIENTS WITH HIGH RISK OF POSTALLOGENEIC STEM CELL TRANSPLANTATION RELAPSE | PFIZER INC. | $32,860 | 0 |
| GLASDEGIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $23,340 | 7 |
| A PHASE 2 STUDY OF PF04449913 FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME PATIENTS WITH HIGH RISK OF POSTALLOGENEIC STEM CELL TRANSPLANTATION RELAPSE | PFIZER INC. | $19,268 | 0 |
Top Doctors Receiving Payments for DAURISMO — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pediatric Hematology-Oncology | Boston, MA | $1,560 | 2 |
| , MD | Hematology & Oncology | Milwaukee, WI | $1,560 | 2 |
| , D.O | Hematology | Fort Worth, TX | $1,554 | 6 |
| , MD | Hematology | Indianapolis, IN | $1,500 | 1 |
| , M.D | Hematology & Oncology | Memphis, TN | $1,500 | 1 |
| , M.D | Hematology & Oncology | Elk Grove Village, IL | $1,500 | 1 |
| , M.D | Internal Medicine | Allentown, PA | $1,500 | 1 |
| , M.D | Hematology & Oncology | Rosedale, MD | $1,500 | 1 |
| , MD | Hematology & Oncology | Fountain Hill, PA | $1,500 | 1 |
| , MD | Hematology & Oncology | Las Vegas, NV | $1,500 | 1 |
| , MD | Hematology & Oncology | Scarborough, ME | $1,500 | 1 |
| , M.D | Hematology & Oncology | New Orleans, LA | $1,500 | 1 |
| , M.D | Hematology & Oncology | Sylacauga, AL | $1,400 | 2 |
| , MBBS | Hematology & Oncology | Houston, TX | $1,390 | 4 |
| , DO | Pediatric Hematology-Oncology | Raleigh, NC | $850.00 | 1 |
| , MD | Pediatric Hematology-Oncology | New Haven, CT | $780.00 | 1 |
| , M.D | Hematology & Oncology | Norfolk, NE | $600.00 | 1 |
| , MD | Medical Oncology | Lancaster, OH | $600.00 | 1 |
| , MD | Hematology & Oncology | Mattoon, IL | $600.00 | 1 |
| , M.D | Body Imaging | Boston, MA | $250.00 | 3 |
| , MD | Body Imaging | Boston, MA | $250.00 | 3 |
| , MD PHD | Hematology | Seattle, WA | $112.33 | 1 |
| , M.D | Internal Medicine | Denton, TX | $42.80 | 4 |
| , MD | Hematology & Oncology | Denton, TX | $42.80 | 4 |
| , MD, FACP | Hematology & Oncology | Las Vegas, NV | $37.48 | 3 |
Ad
Manufacturing Companies
- PFIZER INC. $15.8M
- PFIZER INTERNATIONAL LLC $10,139
Product Information
- Type Drug
- Total Payments $15.8M
- Total Doctors 183
- Transactions 1,422
About DAURISMO
DAURISMO is a drug associated with $15.8M in payments to 183 healthcare providers, recorded across 1,422 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2018 to 2024. In 2024, $671,893 was paid across 9 transactions to 1 doctors.
The most common payment nature for DAURISMO is "Unspecified" ($15.3M, 97.0% of total).
DAURISMO is associated with 13 research studies, including "A RANDOMIZED 11 DOUBLEBLIND MULTICENTER PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB PF04449913 OR AZACITIDINE AZA WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA" ($6.8M).